Guggenheim Reiterates “Buy” Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Guggenheim reaffirmed their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report published on Friday,Benzinga reports. Guggenheim currently has a $64.00 target price on the biopharmaceutical company’s stock. Several other analysts have also recently issued reports on RARE. Piper Sandler lowered their price objective on shares of Ultragenyx Pharmaceutical from […]
Guggenheim reaffirmed their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report published on Friday,Benzinga reports. Guggenheim currently has a $64.00 target price on the biopharmaceutical company’s stock. Several other analysts have also recently issued reports on RARE. Piper Sandler lowered their price objective on shares of Ultragenyx Pharmaceutical from […]
